Back to search results

Observational Study of Redifferentiating Medications for Thyroid Cancer

This study is gathering information about how redifferentiating medications are used as a standard treatment for thyroid cancer that has not responded to radioactive iodine (RAI-refractory thyroid cancer) or is unlikely to respond. It's an observational study, meaning researchers will collect data from your regular doctor visits. The main goal is to track any side effects (adverse events) you experience over two years. You might be able to join if you are at least 18 years old, have been diagnosed with RAI-refractory thyroid cancer, and will be receiving redifferentiation agents before planned radioactive iodine treatment as part of your usual care. The study aims to enroll 100 participants.

Study design
This is an observational study, also called a registry study, which means researchers will collect information from your regular care. It plans to include 100 participants.
What's involved
You would have follow-up visits at intervals determined by your usual clinical practice. During these visits, your tolerance of medication and any side effects will be recorded.
Compensation
Not stated in the trial record.
Follow-up
Adverse events will be collected in every visit, and measured over a period of 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05733013

A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer

Recruiting
Not specifiedAges 18+Observational
Memorial Sloan Kettering Cancer Center
~100 participants
Updated 2026-04-27 on ClinicalTrials.gov
What's tested:Surveillance Visit

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Adverse events will be collected in every visit
Measured over 2 years

Conditions

Thyroid Cancer
Thyroid
Refractory Thyroid Cancer

Explore related trials

Thyroid Gland Carcinoma

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Laura Boucai, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Laura Boucai, MD
[email protected]
646-608-3906
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients ≥ 18 years old at time of consent
Patients diagnosed with RAI refractory thyroid cancer or unlikely to respond to RAI.
Patients who will receive redifferentiation agents prior to planned diagnostic and/or therapeutic use of radioactive iodine as part of routine clinical care.
Patients who have never received redifferentiation agents outside of a clinical trial or have received redifferentiation agents in the context of a clinical trial will be enrolled after the clinical team has decided to proceed with a redifferentiation agent as part of routine clinical care prior to diagnostic and/or therapeutic radioactive iodine administration.
Patients previously treated with redifferentiation agents as part of clinical care prior to diagnostic and/or therapeutic radioactive iodine administration who are willing to provide retrospectively collected data surrounding the time of the previous treatment and will provide prospective data from the time of consent.

Exclusion

RAI refractory thyroid cancer patients that will receive redifferentiation agents prior to diagnostic and/or therapeutic use of radioactive iodine as part of a prospective clinical trial.

What this trial measures

  • Adverse events will be collected in every visit2 years

    The primary objective of this protocol is to prospectively collect data on patients with radio-iodine refractory thyroid cancer or patients unlikely to respond to radioactive iodine prior, during and after initiation of redifferentiating agents used as part of routine clinical care with or without radioactive iodine treatment.